

SEQUENCE LISTING

<110> Janssen Pharmaceutica NV

<120> Antibody-Coupled Cyclic Peptide Tyrosine Tyrosine Compounds as Modulators of Neuropeptide Y Receptors

<130> PRD3436

<150> US62/413,613

<151> 2016-10-27

<150> US62/413,586

<151> 2016-10-27

<160> 156

<170> PatentIn version 3.5

<210> 1

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> Cyclic PYY Peptide Compound

<220>

<221> Ala

<222> (1)..(1)

<223> Ala with chemical modification as described in the specification

<220>

<221> Lys

<222> (10)..(10)

<223> Lys with chemical modification as described in the specification

<220>

<221> Cys

<222> (30)..(30)

<223> Cys, wherein Cys is a homocysteine with chemical modification as described in the specification

<220>

<221> Arg

<222> (34)..(34)

<223> Arg with chemical modification as described in the specification

<400> 1

Ala	Ile	Lys	Pro	Glu	Ala	Pro	Gly	Glu	Lys	Ala	Ser	Pro	Glu	Glu	Leu
1				5				10					15		

Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Cys Thr Arg
20 25 30

Gln Arg Tyr
35

<210> 2
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with chemical modification as described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cyse, wherein Cys is homocysteine with chemical modification as described in the specification

<400> 2

Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Cys Thr Arg Gln
20 25 30

Arg Tyr

<210> 3
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile

<222> (1)..(1)
<223> Ile with the chemical modification as described in the specification

<220>
<221> Leu
<222> (29)..(29)
<223> Leu, wherein Leu is a norleucine with the chemical modification as described in the specification

<400> 3

Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Leu Thr Arg Gln
20 25 30

Arg Tyr

<210> 4
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification as described in the specification

<220>
<221> Lys
<222> (9)..(9)
<223> Lys with the chemical modification as described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys, wherein cys is a homocysteine with the chemical modification as described in the specification

<400> 4

Ile Lys Pro Glu Ala Pro Gly Glu Lys Ala Ser Pro Glu Glu Leu Asn

1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Cys Thr Arg Gln
20 25 30

Arg Tyr

<210> 5
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification as described in the
specification

<220>
<221> Lys
<222> (9)..(9)
<223> Lys with the chemical modification as described in the
specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys, wherein cys is homocysteine with the chemical modification
as described in the specification

<400> 5

Ile Lys Pro Glu Ala Pro Gly Glu Lys Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Cys Thr Arg Gln
20 25 30

Arg Tyr

<210> 6
<211> 34

<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification as described in the specification

<220>
<221> Lys
<222> (9)..(9)
<223> Lys with the chemical modification as described in the specification

<220>
<221> Leu
<222> (29)..(29)
<223> Leu, wherein the leu is norleucine with the chemical modification as described in the specification

<400> 6

Ile	Lys	Pro	Glu	Ala	Pro	Gly	Glu	Lys	Ala	Ser	Pro	Glu	Glu	Leu	Asn
1				5					10					15	

Arg	Tyr	Tyr	Ala	Ser	Leu	Arg	His	Tyr	Leu	Asn	Leu	Leu	Thr	Arg	Gln
			20					25						30	

Arg Tyr

<210> 7
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification as described in the specification

<220>
<221> Lys
<222> (7)..(7)
<223> Lys with the chemical modification as described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys, wherein cys is homocysteine with the chemical modification as described in the specification

<400> 7

Ile Lys Pro Glu Ala Pro Lys Glu Asp Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Cys Thr Arg Gln
20 25 30

Arg Tyr

<210> 8
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification as described in the specification

<220>
<221> Lys
<222> (28)..(28)
<223> Lys with the chemical modification as described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys, wherein cys is homocysteine with the chemical modification as described in the specification

<400> 8

Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Lys Cys Thr Arg Gln
20 25 30

Arg Tyr

<210> 9
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification as described in the
specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys, wherein cys is a homocysteine with the chemical modification
as described in the specification

<220>
<221> Arg
<222> (33)..(33)
<223> Arg with the chemical modification as described in the
specification

<400> 9

Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Cys Thr Arg Gln
20 25 30

Arg Tyr

<210> 10
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification as described in the specification

<220>
<221> Lys
<222> (28)..(28)
<223> Lys with the chemical modification as described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys, wherein cys is homocysteine with the chemical modification as described in the specification

<400> 10

Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Lys Cys Thr Arg
20 25 30

Gln Arg Tyr
35

<210> 11
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification as described in the

specification

<220>

<221> Lys

<222> (28)..(28)

<223> Lys with the chemical modification as described in the specification

<220>

<221> Cys

<222> (29)..(29)

<223> Cys, wherein cys is homocysteine with the chemical modification as described in the specification

<220>

<221> Arg

<222> (33)..(33)

<223> Arg with the chemical modification as described in the specification

<400> 11

Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Lys Cys Thr Arg
20 25 30

Gln Arg Tyr
35

<210> 12

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Cyclic PYY Peptide Compound

<220>

<221> Ile

<222> (1)..(1)

<223> Ile with the chemical modification as described in the specification

<220>

<221> Cys

<222> (29)..(29)

<223> Cys, wherein the cys is homocysteine with the chemical modification as described in the specification

<220>
<221> Arg
<222> (33)..(33)
<223> Arg with the chemical modification as described in the specification

<400> 12

Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Cys Thr Arg Gln
20 25 30

Arg Tyr

<210> 13
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification as described in the specification

<220>
<221> Lys
<222> (28)..(28)
<223> Lys with the chemical modification as described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys, wherein the cys is homocysteine with the chemical modification as described in the specification

<220>
<221> Arg
<222> (33)..(33)
<223> Arg with the chemical modification as described in the specification

<400> 13

Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Lys Cys Thr Arg Gln
20 25 30

Arg Tyr

<210> 14

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Cyclic PYY Peptide Compound

<220>

<221> Ile

<222> (1)..(1)

<223> Ile with the chemical modification as described in the
specification

<220>

<221> Lys

<222> (28)..(28)

<223> Lys with the chemical modification as described in the
specification

<220>

<221> Cys

<222> (29)..(29)

<223> Cys, wherein the cys is homocysteine with the chemical
modification as described in the specification

<220>

<221> Arg

<222> (33)..(33)

<223> Arg with the chemical modification as described in the
specification

<400> 14

Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Lys Cys Thr Arg Gln

20

25

30

Arg Tyr

<210> 15
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Cyclic PYY Peptide Compound

<220>
 <221> Lys
 <222> (1)..(1)
 <223> Lys with the chemical modification as described in the specification

<220>
 <221> Lys
 <222> (27)..(27)
 <223> Lys with the chemical modification as described in the specification

<220>
 <221> Cys
 <222> (28)..(28)
 <223> Cys, wherein cys is homocysteine with the chemical modification as described in the specification

<400> 15

Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn Arg
 1 5 10 15

Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Lys Cys Thr Arg Gln Arg
 20 25 30

Tyr

<210> 16
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>

<223> Cyclic PYY Peptide Compound

<220>

<221> Lys

<222> (1)..(1)

<223> Lys with the chemical modification as described in the specification

<220>

<221> Lys

<222> (27)..(27)

<223> Lys with the chemical modification as described in the specification

<220>

<221> Cys

<222> (28)..(28)

<223> Cys, wherein the cys is homocysteine with the chemical modification as described in the specification

<400> 16

Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn Arg
1 5 10 15

Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Lys Cys Thr Arg Gln Arg
20 25 30

Tyr

<210> 17

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Cyclic PYY Peptide Compound

<220>

<221> Ile

<222> (1)..(1)

<223> Ile with the chemical modification as described in the specification

<220>

<221> Lys

<222> (28)..(28)

<223> Lys with the chemical modification as described in the

specification

<220>

<221> Cys

<222> (29)..(29)

<223> Cys, wherein the cys is a homocysteine with the chemical modification as described in the specification

<400> 17

Ile Ala Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Lys Cys Thr Arg Gln
20 25 30

Arg Tyr

<210> 18

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Cyclic PYY Peptide Compound

<220>

<221> Ile

<222> (1)..(1)

<223> Ile with the chemical modification as described in the specification

<220>

<221> Lys

<222> (28)..(28)

<223> Lys with the chemical modification as described in the specification

<220>

<221> Cys

<222> (29)..(29)

<223> Cys, wherein cys is homocysteine with the chemical modification as described in the specification

<400> 18

Ile Glu Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Lys Cys Thr Arg Gln
20 25 30

Arg Tyr

<210> 19
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification as described in the
specification

<220>
<221> Lys
<222> (28)..(28)
<223> Lys with the chemical modification as described in the
specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys with the chemical modification as described in the
specification

<220>
<221> Arg
<222> (33)..(33)
<223> Arg with the chemical modification as described in the
specification

<400> 19

Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Lys Cys Thr Arg Gln
20 25 30

Arg Tyr

<210> 20
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification as described in the specification

<220>
<221> Lys
<222> (28)..(28)
<223> Lys with the chemical modification as described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys with the chemical modification as described in the specification

<220>
<221> Arg
<222> (33)..(33)
<223> Arg with the chemical modification as described in the specification

<400> 20

Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Lys Cys Thr Arg Gln
20 25 30

Arg Tyr

<210> 21
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification as described in the specification

<220>
<221> Lys
<222> (28)..(28)
<223> Lys with the chemical modification as described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys, wherein cys is a homocysteine with the chemical modification as described in the specification

<400> 21

Ile Ala Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg Ala Tyr Leu Asn Lys Cys Thr Arg Gln
20 25 30

Arg Tyr

<210> 22
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification as described in the specification

<220>
<221> Lys
<222> (28)..(28)

<223> Lys with the chemical modification as described in the specification

<220>

<221> Cys

<222> (29)..(29)

<223> Cys, wherein the cys is a homocysteine with the chemical modification as described in the specification

<400> 22

Ile Glu Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg Ala Tyr Leu Asn Lys Cys Thr Arg Gln
20 25 30

Arg Tyr

<210> 23

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Cyclic PYY Peptide Compound

<220>

<221> Ile

<222> (1)..(1)

<223> Ile with the chemical modification as described in the specification

<220>

<221> Lys

<222> (28)..(28)

<223> Lys with the chemical modification as described in the specification

<220>

<221> Cys

<222> (29)..(29)

<223> Cys, wherein cys is a homocysteine with the chemical modification as described in the specification

<220>

<221> Arg

<222> (33)..(33)

<223> Arg with the chemical modification as described in the

specification

<400> 23

Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Lys Cys Thr Arg Gln
20 25 30

Arg Tyr

<210> 24

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Cyclic PYY Peptide Compound

<220>

<221> Ile

<222> (1)..(1)

<223> Ile with the chemical modification as described in the
specification

<220>

<221> Lys

<222> (28)..(28)

<223> Lys with the chemical modification as described in the
specification

<220>

<221> Cys

<222> (29)..(29)

<223> Cys, wherein cys is homocysteine with the chemical modification
as described in the specification

<220>

<221> Arg

<222> (33)..(33)

<223> Arg with the chemical modification as described in the
specification

<400> 24

Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Lys Cys Thr Arg Gln
20 25 30

Arg Tyr

<210> 25
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification as described in the
specification

<220>
<221> Lys
<222> (28)..(28)
<223> Lys with the chemical modification as described in the
specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys, wherein cys is a homocysteine with the chemical modification
as described in the specification

<220>
<221> Arg
<222> (33)..(33)
<223> Arg with the chemical modification as described in the
specification

<400> 25

Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Lys Cys Thr Arg Gln
20 25 30

Arg Tyr

<210> 26
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification described in the application

<220>
<221> Lys
<222> (28)..(28)
<223> Lys with the chemical modification described in the application

<220>
<221> Cys
<222> (29)..(29)
<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the application

<220>
<221> Arg
<222> (33)..(33)
<223> Arg with the chemical modification described in the application

<400> 26

Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Lys Cys Thr Arg Gln
20 25 30

Arg Tyr

<210> 27
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification described in the specification

<220>
<221> Lys
<222> (28)..(28)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys, wherein the cys is homocysteine with the chemical modification described in the specification

<220>
<221> Arg
<222> (33)..(33)
<223> Arg with the chemical modification described in the specification

<400> 27

Ile	Lys	Pro	Glu	Ala	Pro	Gly	Glu	Asp	Ala	Ser	Pro	Glu	Glu	Leu	Asn
1				5				10						15	

Arg	Tyr	Tyr	Ala	Ser	Leu	Arg	His	Tyr	Leu	Asn	Lys	Cys	Thr	Arg	Gln
			20					25					30		

Arg Tyr

<210> 28
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Lys
<222> (1)..(1)
<223> Lys with the chemical modification described in the specification

<220>
<221> Lys
<222> (27)..(27)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (28)..(28)
<223> Cys, wherein the cys is a homocysteine with the chemical
modification described in the specification

<220>
<221> Arg
<222> (32)..(32)
<223> Arg with the chemical modification described in the specification

<400> 28

Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn Arg
1 5 10 15

Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Lys Cys Thr Arg Gln Arg
20 25 30

Tyr

<210> 29
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Lys
<222> (1)..(1)
<223> Lys with the chemical modification described in the specification

<220>
<221> Lys
<222> (27)..(27)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (28)..(28)
<223> Cys, wherein the cys is a homocysteine with the chemical
modification described in the specification

<220>
<221> Arg
<222> (32)..(32)

<223> Arg with the chemical modification described in the specification

<400> 29

Lys	Pro	Glu	Ala	Pro	Gly	Glu	Asp	Ala	Ser	Pro	Glu	Glu	Leu	Asn	Arg
1				5					10					15	

Tyr	Tyr	Ala	Ser	Leu	Arg	His	Tyr	Leu	Asn	Lys	Cys	Thr	Arg	Gln	Arg
			20					25					30		

Tyr

<210> 30

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> Cyclic PYY Peptide Compound

<220>

<221> Lys

<222> (1)..(1)

<223> Lys with the chemical modification described in the specification

<220>

<221> Lys

<222> (27)..(27)

<223> Lys with the chemical modification described in the specification

<220>

<221> Cys

<222> (28)..(28)

<223> Cys with the chemical modification described in the specification

<220>

<221> Arg

<222> (32)..(32)

<223> Arg with the chemical modification described in the specification

<400> 30

Lys	Pro	Glu	Ala	Pro	Gly	Glu	Asp	Ala	Ser	Pro	Glu	Glu	Leu	Asn	Arg
1				5					10					15	

Tyr	Tyr	Ala	Ser	Leu	Arg	His	Tyr	Leu	Asn	Lys	Cys	Thr	Arg	Gln	Arg
			20					25					30		

Tyr

<210> 31
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification described in the specification

<220>
<221> Lys
<222> (28)..(28)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>
<221> Arg
<222> (33)..(33)
<223> Arg with the chemical modification described in the specification

<400> 31

Ile	Lys	Pro	Glu	Ala	Pro	Gly	Glu	Asp	Ala	Ser	Pro	Glu	Glu	Leu	Asn
1				5					10					15	

Arg	Tyr	Tyr	Ala	Ser	Leu	Arg	His	Tyr	Leu	Asn	Lys	Cys	Thr	Arg	Gln
			20					25					30		

Arg Tyr

<210> 32
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification described in the specification

<220>
<221> Lys
<222> (28)..(28)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>
<221> Arg
<222> (33)..(33)
<223> Arg with the chemical modification described in the specification

<400> 32

Ile	Ala	Pro	Glu	Ala	Pro	Gly	Glu	Asp	Ala	Ser	Pro	Glu	Glu	Leu	Asn
1				5					10					15	

Arg	Tyr	Tyr	Ala	Ser	Leu	Arg	Ala	Tyr	Leu	Asn	Lys	Cys	Thr	Arg	Gln
			20					25					30		

Arg Tyr

<210> 33
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification described in the specification

<220>

<221> Lys
<222> (28)..(28)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>
<221> Gln
<222> (32)..(32)
<223> Gln with the chemical modification described in the specification

<220>
<221> Arg
<222> (33)..(33)
<223> Arg with the chemical modification described in the specification

<400> 33

Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Lys Cys Thr Arg Gln
20 25 30

Arg Tyr

<210> 34
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Lys
<222> (1)..(1)
<223> Lys with the chemical modification described in the specification

<220>
<221> Lys
<222> (27)..(27)
<223> Lys with the chemical modification described in the specification

<220>

<221> Cys
<222> (28)..(28)
<223> Cys with the chemical modification described in the specification

<220>
<221> Arg
<222> (32)..(32)
<223> Arg with the chemical modification described in the specification

<400> 34

Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn Arg
1 5 10 15

Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Lys Cys Thr Arg Gln Arg
20 25 30

Tyr

<210> 35
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification described in the specification

<220>
<221> Lys
<222> (28)..(28)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>
<221> Arg
<222> (33)..(33)
<223> Arg with the chemical modification described in the specification

<400> 35

Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Lys Cys Thr Arg Gln
20 25 30

Arg Tyr

<210> 36
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Lys
<222> (1)..(1)
<223> Lys with the chemical modification described in the specification

<220>
<221> Lys
<222> (27)..(27)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (28)..(28)
<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>
<221> Arg
<222> (32)..(32)
<223> Arg with the chemical modification described in the specification

<400> 36

Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn Arg
1 5 10 15

Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Lys Cys Thr Arg Gln Arg
20 25 30

Tyr

<210> 37
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification described in the specification

<220>
<221> Lys
<222> (28)..(28)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys with the chemical modification described in the specification

<220>
<221> Arg
<222> (33)..(33)
<223> Arg with the chemical modification described in the specification

<400> 37

Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Lys Cys Thr Arg Gln
20 25 30

Arg Tyr

<210> 38
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification described in the specification

<220>
<221> Lys
<222> (28)..(28)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>
<221> Arg
<222> (33)..(33)
<223> Arg with the chemical modification described in the specification

<400> 38

Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Lys Cys Thr Arg Gln
20 25 30

Arg Tyr

<210> 39
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification described in the specification

<220>
<221> Lys
<222> (28)..(28)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys, wherein the cys is a homocysteine with the chemical
modification described in the specification

<220>
<221> Arg
<222> (33)..(33)
<223> Arg with the chemical modification described in the specification

<400> 39

Ile Ser Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Lys Cys Thr Arg Gln
20 25 30

Arg Tyr

<210> 40
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification described in the specification

<220>
<221> Lys
<222> (28)..(28)
<223> Lys with the chemical modification described in the specification

<220>
<221> Leu
<222> (29)..(29)
<223> Leu, wherein the leu is a norleucine with the chemical
modification described in the specification

<220>
<221> Arg
<222> (33)..(33)

<223> Arg with the chemical modification described in the specification

<400> 40

Ile	Lys	Pro	Glu	Ala	Pro	Gly	Glu	Asp	Ala	Ser	Pro	Glu	Glu	Leu	Asn
1				5					10					15	

Arg	Tyr	Tyr	Ala	Ser	Leu	Arg	His	Tyr	Leu	Asn	Lys	Leu	Thr	Arg	Gln
			20					25					30		

Arg Tyr

<210> 41

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Cyclic PYY Peptide Compound

<220>

<221> Ile

<222> (1)..(1)

<223> Ile with the chemical modification described in the specification

<220>

<221> Lys

<222> (28)..(28)

<223> Lys with the chemical modification described in the specification

<220>

<221> Leu

<222> (29)..(29)

<223> Leu, wherein the leu is a norleucine with the chemical modification described in the specification

<220>

<221> Arg

<222> (33)..(33)

<223> Arg with the chemical modification described in the specification

<400> 41

Ile	Lys	Pro	Glu	Ala	Pro	Gly	Glu	Asp	Ala	Ser	Pro	Glu	Glu	Leu	Asn
1				5					10					15	

Arg	Tyr	Tyr	Ala	Ser	Leu	Arg	His	Tyr	Leu	Asn	Lys	Leu	Thr	Arg	Gln
			20					25					30		

Arg Tyr

<210> 42
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification described in the specification

<220>
<221> Lys
<222> (28)..(28)
<223> Lys with the chemical modification described in the specification

<220>
<221> Leu
<222> (29)..(29)
<223> Leu, wherein the leu is a norleucine with the chemical modification described in the specification

<220>
<221> Arg
<222> (33)..(33)
<223> Arg with the chemical modification described in the specification

<400> 42

Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Lys Leu Thr Arg Gln
20 25 30

Arg Tyr

<210> 43
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification described in the specification

<220>
<221> Lys
<222> (28)..(28)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>
<221> Arg
<222> (33)..(33)
<223> Arg with the chemical modification described in the specification

<400> 43

Ile	Lys	Pro	Glu	Ala	Pro	Gly	Glu	Asp	Ala	Ser	Pro	Glu	Glu	Leu	Asn
1				5					10					15	

Arg	Tyr	Tyr	Ala	Ser	Leu	Arg	His	Tyr	Leu	Asn	Lys	Cys	Thr	Arg	Gln
			20					25					30		

Arg Tyr

<210> 44
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification described in the specification

<220>
<221> Lys
<222> (9)..(9)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>
<221> Arg
<222> (33)..(33)
<223> Arg with the chemical modification described in the specification

<400> 44

Ile	Lys	Pro	Glu	Ala	Pro	Gly	Glu	Lys	Ala	Ser	Pro	Glu	Glu	Leu	Asn
1				5					10					15	

Arg	Tyr	Tyr	Ala	Ser	Leu	Arg	His	Tyr	Leu	Asn	Leu	Cys	Thr	Arg	Gln
			20					25					30		

Arg Tyr

<210> 45
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification described in the specification

<220>
<221> Lys
<222> (9)..(9)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>
<221> Arg
<222> (33)..(33)
<223> Arg with the chemical modification described in the specification

<400> 45

Ile Lys Pro Glu Ala Pro Gly Glu Lys Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Cys Thr Arg Gln
20 25 30

Arg Tyr

<210> 46
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification described in the specification

<220>
<221> Lys
<222> (28)..(28)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys, wherein the cys is a homocysteine with the chemical
modification described in the specification

<220>
<221> Arg
<222> (33)..(33)
<223> Arg with the chemical modification described in the specification

<400> 46

Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Lys Cys Thr Arg Gln
20 25 30

Arg Tyr

<210> 47
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification described in the specification

<220>
<221> Lys
<222> (5)..(5)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys, wherein the cys is a homocysteine with the chemical
modification described in the specification

<220>
<221> Arg
<222> (33)..(33)
<223> Arg with the chemical modification described in the specification

<400> 47

Ile Lys Pro Glu Lys Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Cys Thr Arg Gln
20 25 30

Arg Tyr

<210> 48
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification described in the specification

<220>
<221> Lys
<222> (20)..(20)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>
<221> Arg
<222> (33)..(33)
<223> Arg with the chemical modification described in the specification

<400> 48

Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Lys Ser Leu Arg His Tyr Leu Asn Leu Cys Thr Arg Gln
20 25 30

Arg Tyr

<210> 49
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>

<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification described in the specification

<220>
<221> Lys
<222> (28)..(28)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>
<221> Arg
<222> (33)..(33)
<223> Arg with the chemical modification described in the specification

<400> 49

Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Lys Cys Thr Arg Gln
20 25 30

Arg Tyr

<210> 50
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification described in the specification

<220>
<221> Lys
<222> (21)..(21)
<223> Lys with the chemical modification described in the specification

<220>

<221> Cys
<222> (29)..(29)
<223> Cys, wherein the cys is a homocysteine with the chemical
modification described in the specification

<220>
<221> Arg
<222> (33)..(33)
<223> Arg with the chemical modification described in the specification

<400> 50

Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Lys Leu Arg His Tyr Leu Asn Leu Cys Thr Arg Gln
20 25 30

Arg Tyr

<210> 51
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification described in the specification

<220>
<221> Lys
<222> (28)..(28)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys, wherein the cys is a homocysteine with the chemical
modification described in the specification

<220>
<221> Arg
<222> (33)..(33)
<223> Arg with the chemical modification described in the specification

<400> 51

Ile Ser Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Lys Cys Thr Arg Gln
20 25 30

Arg Tyr

<210> 52

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Cyclic PYY Peptide Compound

<220>

<221> Ile

<222> (1)..(1)

<223> Ile with the chemical modification described in the specification

<220>

<221> Lys

<222> (9)..(9)

<223> Lys with the chemical modification described in the specification

<220>

<221> Cys

<222> (29)..(29)

<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>

<221> Arg

<222> (33)..(33)

<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<400> 52

Ile Lys Pro Glu Ala Pro Gly Glu Lys Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Cys Thr Arg Gln
20 25 30

Arg Tyr

<210> 53
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification described in the specification

<220>
<221> Lys
<222> (9)..(9)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>
<221> Arg
<222> (33)..(33)
<223> Arg with the chemical modification described in the specification

<400> 53

Ile Lys Pro Glu Ala Pro Gly Glu Lys Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Cys Thr Arg Gln
20 25 30

Arg Tyr

<210> 54
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification described in the specification

<220>
<221> Lys
<222> (9)..(9)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>
<221> Arg
<222> (33)..(33)
<223> Arg with the chemical modification described in the specification

<400> 54

Ile Lys Pro Glu Ala Pro Gly Glu Lys Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Cys Thr Arg Gln
20 25 30

Arg Tyr

<210> 55
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification described in the specification

<220>

<221> Lys
<222> (21)..(21)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>
<221> Arg
<222> (33)..(33)
<223> Arg with the chemical modification described in the specification

<400> 55

Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Lys Leu Arg His Tyr Leu Asn Leu Cys Thr Arg Gln
20 25 30

Arg Tyr

<210> 56
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification described in the specification

<220>
<221> Lys
<222> (28)..(28)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<400> 56

Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Lys Cys Thr Arg Gln
20 25 30

Arg Tyr

<210> 57

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Cyclic PYY Peptide Compound

<220>

<221> Ile

<222> (1)..(1)

<223> Ile with the chemical modification described in the specification

<220>

<221> Lys

<222> (28)..(28)

<223> Lys with the chemical modification described in the specification

<220>

<221> Cys

<222> (29)..(29)

<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<400> 57

Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Lys Cys Thr Arg Gln
20 25 30

Arg Tyr

<210> 58

<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification described in the specification

<220>
<221> Lys
<222> (28)..(28)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>
<221> Arg
<222> (33)..(33)
<223> Arg with the chemical modification described in the specification

<400> 58

Ile	Lys	Pro	Glu	Ala	Pro	Gly	Glu	Asp	Ala	Ser	Pro	Glu	Glu	Leu	Asn
1				5					10					15	

Arg	Tyr	Tyr	Ala	Ser	Leu	Arg	His	Tyr	Leu	Asn	Lys	Cys	Thr	Arg	Gln
			20					25					30		

Arg Tyr

<210> 59
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile

<222> (1)..(1)
<223> Ile with the chemical modification described in the specification

<220>
<221> Lys
<222> (20)..(20)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>
<221> Arg
<222> (33)..(33)
<223> Arg with the chemical modification described in the specification

<400> 59

Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Lys Ser Leu Arg His Tyr Leu Asn Leu Cys Thr Arg Gln
20 25 30

Arg Tyr

<210> 60
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification described in the specification

<220>
<221> Lys
<222> (5)..(5)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys

<222> (29)..(29)
 <223> Cys, wherein the cys is a homocysteine with the chemical
 modification described in the specification

 <220>
 <221> Arg
 <222> (33)..(33)
 <223> Arg with the chemical modification described in the specification

 <400> 60

Ile	Lys	Pro	Glu	Lys	Pro	Gly	Glu	Asp	Ala	Ser	Pro	Glu	Glu	Leu	Asn
1				5					10					15	

Arg	Tyr	Tyr	Ala	Ser	Leu	Arg	His	Tyr	Leu	Asn	Leu	Cys	Thr	Arg	Gln
			20					25					30		

Arg Tyr

<210> 61
 <211> 34
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Cyclic PYY Peptide Compound

<220>
 <221> Ile
 <222> (1)..(1)
 <223> Ile with the chemical modification described in the specification

<220>
 <221> Lys
 <222> (28)..(28)
 <223> Lys with the chemical modification described in the specification

<220>
 <221> Cys
 <222> (29)..(29)
 <223> Cys, wherein the cys is a homocysteine with the chemical
 modification described in the specification

<220>
 <221> Arg
 <222> (33)..(33)
 <223> Arg with the chemical modification described in the specification

<400> 61

Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Lys Cys Thr Arg Gln
20 25 30

Arg Tyr

<210> 62
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification described in the specification

<220>
<221> Lys
<222> (28)..(28)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>
<221> Arg
<222> (33)..(33)
<223> Arg with the chemical modification described in the specification

<400> 62

Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Lys Cys Thr Arg Gln
20 25 30

Arg Tyr

<210> 63
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification described in the specification

<220>
<221> Lys
<222> (28)..(28)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>
<221> Arg
<222> (33)..(33)
<223> Arg with the chemical modification described in the specification

<400> 63

Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Lys Cys Thr Arg Gln
20 25 30

Arg Tyr

<210> 64
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification described in the specification

<220>
<221> Lys
<222> (28)..(28)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>
<221> Arg
<222> (33)..(33)
<223> Arg with the chemical modification described in the specification

<400> 64

Ile	Lys	Pro	Glu	Ala	Pro	Gly	Glu	Asp	Ala	Ser	Pro	Glu	Glu	Leu	Asn
1			5					10						15	

Arg	Tyr	Tyr	Ala	Ser	Leu	Arg	His	Tyr	Leu	Asn	Lys	Cys	Thr	Arg	Gln
			20					25					30		

Arg Tyr

<210> 65
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification described in the specification

<220>
<221> Lys
<222> (28)..(28)

<223> Lys with the chemical modification described in the specification

<220>

<221> Cys

<222> (29)..(29)

<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>

<221> Arg

<222> (33)..(33)

<223> Arg with the chemical modification described in the specification

<400> 65

Ile	Lys	Pro	Glu	Ala	Pro	Gly	Glu	Asp	Ala	Ser	Pro	Glu	Glu	Leu	Asn
1				5					10					15	

Arg	Tyr	Tyr	Ala	Ser	Leu	Arg	His	Tyr	Leu	Asn	Lys	Cys	Thr	Arg	Gln
			20					25					30		

Arg Tyr

<210> 66

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Cyclic PYY Peptide Compound

<220>

<221> Ile

<222> (1)..(1)

<223> Ile with the chemical modification described in the specification

<220>

<221> Lys

<222> (28)..(28)

<223> Lys with the chemical modification described in the specification

<220>

<221> Cys

<222> (29)..(29)

<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>

<221> Arg

<222> (33)..(33)
<223> Arg with the chemical modification described in the specification

<400> 66

Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Lys Cys Thr Arg Gln
20 25 30

Arg Tyr

<210> 67
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification described in the specification

<220>
<221> Lys
<222> (28)..(28)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>
<221> Arg
<222> (33)..(33)
<223> Arg with the chemical modification described in the specification

<400> 67

Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Lys Cys Thr Arg Gln

Arg Tyr

<210> 68
 <211> 34
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Cyclic PYY Peptide Compound

<220>
 <221> Ile
 <222> (1)..(1)
 <223> Ile with the chemical modification described in the specification

<220>
 <221> Lys
 <222> (9)..(9)
 <223> Lys with the chemical modification described in the specification

<220>
 <221> Cys
 <222> (28)..(28)
 <223> Cys with the chemical modification described in the specification

<220>
 <221> Arg
 <222> (33)..(33)
 <223> Arg with the chemical modification described in the specification

<400> 68

Ile	Lys	Pro	Glu	Ala	Pro	Gly	Glu	Lys	Ala	Ser	Pro	Glu	Glu	Leu	Asn
1				5					10					15	

Arg	Tyr	Tyr	Ala	Ser	Leu	Arg	His	Tyr	Leu	Asn	Cys	Val	Thr	Arg	Gln
			20					25					30		

Arg Tyr

<210> 69
 <211> 35
 <212> PRT
 <213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Gly
<222> (1)..(1)
<223> Gly with the chemical modification described in the specification

<220>
<221> Glu
<222> (30)..(30)
<223> Glu with the chemical modification described in the specification

<220>
<221> Arg
<222> (34)..(34)
<223> Arg with the chemical modification described in the specification

<400> 69

Gly Ile Ser Pro Glu Ala Pro Gly Glu Lys Ala Ser Pro Glu Glu Leu
1 5 10 15

Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Glu Thr Arg
20 25 30

Gln Arg Tyr
35

<210> 70
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Gly
<222> (1)..(1)
<223> Gly with the chemical modification described in the specification

<220>
<221> Glu
<222> (29)..(29)
<223> Glu with the chemical modification described in the specification

<220>

<221> Arg
<222> (34)..(34)
<223> Arg with the chemical modification described in the specification

<400> 70

Gly Ile Ser Pro Glu Ala Pro Gly Glu Lys Ala Ser Pro Glu Glu Leu
1 5 10 15

Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Glu Val Thr Arg
20 25 30

Gln Arg Tyr
35

<210> 71
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Gly
<222> (1)..(1)
<223> Gly with the chemical modification described in the specification

<220>
<221> Glu
<222> (29)..(29)
<223> Glu with the chemical modification described in the specification

<220>
<221> Arg
<222> (34)..(34)
<223> Arg with the chemical modification described in the specification

<400> 71

Gly Ile Ser Pro Glu Ala Pro Gly Glu Lys Ala Ser Pro Glu Glu Leu
1 5 10 15

Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Glu Val Thr Arg
20 25 30

Gln Arg Tyr
35

<210> 72
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Gly
<222> (1)..(1)
<223> Gly with the chemical modification described in the specification

<220>
<221> Lys
<222> (10)..(10)
<223> Lys with the chemical modification described in the specification

<220>
<221> Glu
<222> (29)..(29)
<223> Glu with the chemical modification described in the specification

<220>
<221> Arg
<222> (34)..(34)
<223> Arg with the chemical modification described in the specification

<400> 72

Gly Ile Ser Pro Glu Ala Pro Gly Glu Lys Ala Ser Pro Glu Glu Leu
1 5 10 15

Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Glu Val Thr Arg
20 25 30

Gln Arg Tyr
35

<210> 73
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ala
<222> (1)..(1)
<223> Ala with the chemical modification described in the specification

<220>
<221> Lys
<222> (10)..(10)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (30)..(30)
<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>
<221> Arg
<222> (34)..(34)
<223> Arg with the chemical modification described in the specification

<400> 73

Ala Ile Lys Pro Glu Ala Pro Gly Glu Lys Ala Ser Pro Glu Glu Leu
1 5 10 15

Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Cys Thr Arg
20 25 30

Gln Arg Tyr
35

<210> 74
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ala
<222> (1)..(1)
<223> Ala with the chemical modification described in the specification

<220>
<221> Lys
<222> (10)..(10)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (30)..(30)
<223> Cys, wherein the cys is a homocysteine with the chemical
modification described in the specification

<220>
<221> Arg
<222> (34)..(34)
<223> Arg with the chemical modification described in the specification

<400> 74

Ala	Ile	Lys	Pro	Glu	Ala	Pro	Gly	Glu	Lys	Ala	Ser	Pro	Glu	Glu	Leu
1				5				10					15		

Asn	Arg	Tyr	Tyr	Ala	Ser	Leu	Arg	His	Tyr	Leu	Asn	Leu	Cys	Thr	Arg
			20					25					30		

Gln	Arg	Tyr
		35

<210> 75
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification described in the specification

<220>
<221> Lys
<222> (9)..(9)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys with the chemical modification described in the specification

<220>
<221> Arg
<222> (33)..(33)
<223> Arg with the chemical modification described in the specification

<400> 75

Ile Lys Pro Glu Ala Pro Gly Glu Lys Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Cys Thr Arg Gln
20 25 30

Arg Tyr

<210> 76

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> Cyclic PYY Peptide Compound

<220>

<221> Ala

<222> (1)..(1)

<223> Ala with the chemical modification described in the specification

<220>

<221> Lys

<222> (10)..(10)

<223> Lys with the chemical modification described in the specification

<220>

<221> Lys

<222> (29)..(29)

<223> Lys with the chemical modification described in the specification

<220>

<221> Cys

<222> (30)..(30)

<223> Cys, wherein the cys is a homocysteine with the chemical
modification described in the specification

<220>

<221> Arg

<222> (34)..(34)

<223> Arg with the chemical modification described in the specification

<400> 76

Ala Ile Lys Pro Glu Ala Pro Gly Glu Lys Ala Ser Pro Glu Glu Leu
1 5 10 15

Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Lys Cys Thr Arg
20 25 30

Gln Arg Tyr
35

<210> 77
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ala
<222> (1)..(1)
<223> Ala with the chemical modification described in the specification

<220>
<221> Lys
<222> (10)..(10)
<223> Lys with the chemical modification described in the specification

<220>
<221> Lys
<222> (19)..(19)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (30)..(30)
<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>
<221> Arg
<222> (34)..(34)
<223> Arg with the chemical modification described in the specification

<400> 77

Ala Ile Lys Pro Glu Ala Pro Gly Glu Lys Ala Ser Pro Glu Glu Leu
1 5 10 15

Asn Arg Lys Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Cys Thr Arg
20 25 30

Gln Arg Tyr
35

<210> 78
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ala
<222> (1)..(1)
<223> Ala with the chemical modification described in the specification

<220>
<221> Lys
<222> (10)..(10)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (30)..(30)
<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>
<221> Gln
<222> (33)..(33)
<223> Gln with the chemical modification described in the specification

<220>
<221> Arg
<222> (34)..(34)
<223> Arg with the chemical modification described in the specification

<400> 78

Ala Ile Lys Pro Glu Ala Pro Gly Glu Lys Ala Ser Pro Glu Glu Leu
1 5 10 15

Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Cys Thr Arg
20 25 30

Gln Arg Tyr
35

<210> 79

<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ala
<222> (1)..(1)
<223> Ala with the chemical modification described in the specification

<220>
<221> Lys
<222> (10)..(10)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (30)..(30)
<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>
<221> Arg
<222> (34)..(34)
<223> Arg with the chemical modification described in the specification

<400> 79

Ala	Ile	Lys	Pro	Glu	Ala	Pro	Gly	Glu	Lys	Ala	Ser	Pro	Glu	Glu	Leu
1			5				10					15			

Asn	Arg	Tyr	Tyr	Ala	Ser	Leu	Arg	His	Tyr	Leu	Asn	Leu	Cys	Thr	Arg
		20					25					30			

Gln	Arg	Tyr
		35

<210> 80
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ala

<222> (1)..(1)
<223> Ala with the chemical modification described in the specification

<220>
<221> Lys
<222> (10)..(10)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (30)..(30)
<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>
<221> Arg
<222> (34)..(34)
<223> Arg with the chemical modification described in the specification

<400> 80

Ala Ile Arg Pro Glu Ala Pro Gly Glu Lys Ala Ser Pro Glu Glu Leu
1 5 10 15

Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Trp Cys Thr Arg
20 25 30

Gln Arg Tyr
35

<210> 81
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification described in the specification

<220>
<221> Lys
<222> (9)..(9)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys

<222> (29)..(29)
<223> Cys with the chemical modification described in the specification

<220>
<221> Arg
<222> (33)..(33)
<223> Arg with the chemical modification described in the specification

<400> 81

Ile Arg Pro Glu Ala Pro Gly Glu Lys Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Trp Cys Thr Arg Gln
20 25 30

Arg Tyr

<210> 82
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Lys
<222> (1)..(1)
<223> Lys with the chemical modification described in the specification

<220>
<221> Lys
<222> (8)..(8)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (28)..(28)
<223> Cys with the chemical modification described in the specification

<220>
<221> Arg
<222> (32)..(32)
<223> Arg with the chemical modification described in the specification

<400> 82

Lys Pro Glu Ala Pro Gly Glu Lys Ala Ser Pro Glu Glu Leu Asn Arg

1 5 10 15

Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Cys Thr Arg Gln Arg
20 25 30

Tyr

<210> 83
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification described in the specification

<220>
<221> Lys
<222> (9)..(9)
<223> Lys with the chemical modification described in the specification

<220>
<221> Leu
<222> (29)..(29)
<223> Leu, wherein the leu is a norleucine with the chemical
modification described in the specification

<220>
<221> Arg
<222> (33)..(33)
<223> Arg with the chemical modification described in the specification

<400> 83

Ile Lys Pro Glu Ala Pro Gly Glu Lys Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Leu Val Thr Arg
20 25 30

Gln Arg Tyr
35

<210> 84
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification described in the specification

<220>
<221> Lys
<222> (9)..(9)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>
<221> Arg
<222> (33)..(33)
<223> Arg with the chemical modification described in the specification

<400> 84

Ile Lys Pro Glu Ala Pro Gly Glu Lys Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Cys Val Thr Arg
20 25 30

Gln Arg Tyr
35

<210> 85
<211> 36
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ala
<222> (1)..(1)
<223> Ala with the chemical modification described in the specification

<220>
<221> Lys
<222> (22)..(22)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (30)..(30)
<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>
<221> Arg
<222> (34)..(34)
<223> Arg with the chemical modification described in the specification

<400> 85

Ala Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu
1 5 10 15

Asn Arg Tyr Tyr Ala Lys Leu Arg His Tyr Leu Asn Leu Cys Val Thr
20 25 30

Arg Gln Arg Tyr
35

<210> 86
<211> 36
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ala
<222> (1)..(1)
<223> Ala with the chemical modification described in the specification

<220>
<221> Lys
<222> (21)..(21)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (30)..(30)
<223> Cys, wherein the cys is a homocysteine with the chemical
modification described in the specification

<220>
<221> Arg
<222> (34)..(34)
<223> Arg with the chemical modification described in the specification

<400> 86

Ala Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu
1 5 10 15

Asn Arg Tyr Tyr Lys Ser Leu Arg His Tyr Leu Asn Leu Cys Val Thr
20 25 30

Arg Gln Arg Tyr
35

<210> 87
<211> 36
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ala
<222> (1)..(1)
<223> Ala with the chemical modification described in the specification

<220>
<221> Lys
<222> (6)..(6)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (30)..(30)
<223> Cys, wherein the cys is a homocysteine with the chemical
modification described in the specification

<220>
<221> Arg
<222> (34)..(34)
<223> Arg with the chemical modification described in the specification

<400> 87

Ala Ile Lys Pro Glu Lys Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu
1 5 10 15

Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Cys Val Thr
20 25 30

Arg Gln Arg Tyr
35

<210> 88

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> Cyclic PYY Peptide Compound

<220>

<221> Gly

<222> (1)..(1)

<223> Gly with the chemical modification described in the specification

<220>

<221> Lys

<222> (10)..(10)

<223> Lys with the chemical modification described in the specification

<220>

<221> Cys

<222> (29)..(29)

<223> Cys with the chemical modification described in the specification

<220>

<221> Arg

<222> (34)..(34)

<223> Arg with the chemical modification described in the specification

<400> 88

Gly Ile Lys Pro Glu Ala Pro Gly Glu Lys Ala Ser Pro Glu Glu Leu
1 5 10 15

Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Cys Val Thr Arg
20 25 30

Gln Arg Tyr
35

<210> 89
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Gly
<222> (1)..(1)
<223> Gly with the chemical modification described in the specification

<220>
<221> Lys
<222> (10)..(10)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys with the chemical modification described in the specification

<220>
<221> Arg
<222> (34)..(34)
<223> Arg with the chemical modification described in the specification

<400> 89

Gly Ile Lys Pro Glu Ala Pro Gly Glu Lys Ala Ser Pro Glu Glu Leu
1 5 10 15

Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Cys Val Thr Arg
20 25 30

Gln Arg Tyr
35

<210> 90
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ala
<222> (1)..(1)
<223> Ala with the chemical modification described in the specification

<220>
<221> Lys
<222> (10)..(10)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys with the chemical modification described in the specification

<220>
<221> Arg
<222> (34)..(34)
<223> Arg with the chemical modification described in the specification

<400> 90

Ala Ile Lys Pro Glu Ala Pro Gly Glu Lys Ala Ser Pro Glu Glu Leu
1 5 10 15

Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Cys Val Thr Arg
20 25 30

Gln Arg Tyr
35

<210> 91
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Gly
<222> (1)..(1)
<223> Gly with the chemical modification described in the specification

<220>
<221> Lys
<222> (10)..(10)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys, wherein the cys is a homocysteine with the chemical
modification described in the specification

<220>
<221> Arg
<222> (34)..(34)
<223> Arg with the chemical modification described in the specification

<400> 91

Gly Ile Lys Pro Glu Ala Pro Gly Glu Lys Ala Ser Pro Glu Glu Leu
1 5 10 15

Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Cys Val Thr Arg
20 25 30

Gln Arg Tyr
35

<210> 92
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ala
<222> (1)..(1)
<223> Ala with the chemical modification described in the specification

<220>
<221> Lys
<222> (10)..(10)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (30)..(30)
<223> Cys, wherein the cys is a homocysteine with the chemical
modification described in the specification

<220>
<221> Arg
<222> (34)..(34)

<223> Arg with the chemical modification described in the specification

<400> 92

Ala Ile Lys Pro Glu Ala Pro Gly Glu Lys Ala Ser Pro Glu Glu Leu
1 5 10 15

Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Cys Thr Arg
20 25 30

Gln Arg Tyr
35

<210> 93

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> Cyclic PYY Peptide Compound

<220>

<221> Gly

<222> (1)..(1)

<223> Gly with the chemical modification described in the specification

<220>

<221> Lys

<222> (10)..(10)

<223> Lys with the chemical modification described in the specification

<220>

<221> Cys

<222> (29)..(29)

<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>

<221> Arg

<222> (34)..(34)

<223> Arg with the chemical modification described in the specification

<400> 93

Gly Ile Lys Pro Glu Ala Pro Gly Glu Lys Ala Ser Pro Glu Glu Leu
1 5 10 15

Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Cys Val Thr Arg
20 25 30

Gln Arg Tyr
35

<210> 94
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ala
<222> (1)..(1)
<223> Ala with the chemical modification described in the specification

<220>
<221> Lys
<222> (10)..(10)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys with the chemical modification described in the specification

<220>
<221> Arg
<222> (34)..(34)
<223> Arg with the chemical modification described in the specification

<400> 94

Ala Ile Lys Pro Glu Ala Pro Gly Glu Lys Ala Ser Pro Glu Glu Leu
1 5 10 15

Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Cys Val Thr Arg
20 25 30

Gln Arg Tyr
35

<210> 95
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Gly
<222> (1)..(1)
<223> Gly with the chemical modification described in the specification

<220>
<221> Lys
<222> (10)..(10)
<223> Lys with the chemical modification described in the specification

<220>
<221> Glu
<222> (29)..(29)
<223> Glu with the chemical modification described in the specification

<220>
<221> Arg
<222> (34)..(34)
<223> Arg with the chemical modification described in the specification

<400> 95

Gly Ile Ser Pro Glu Ala Pro Gly Glu Lys Ala Ser Pro Glu Glu Leu
1 5 10 15

Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Glu Val Thr Arg
20 25 30

Gln Arg Tyr
35

<210> 96
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ala
<222> (1)..(1)
<223> Ala with the chemical modification described in the specification

<220>
<221> Lys

<222> (10)..(10)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (30)..(30)
<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>
<221> Arg
<222> (34)..(34)
<223> Arg with the chemical modification described in the specification

<400> 96

Ala	Ile	Lys	Pro	Glu	Ala	Pro	Gly	Glu	Lys	Ala	Ser	Pro	Glu	Glu	Leu
1				5					10					15	

Asn	Arg	Tyr	Tyr	Ala	Ser	Leu	Arg	His	Tyr	Leu	Asn	Leu	Cys	Thr	Arg
			20					25					30		

Gln	Arg	Tyr
		35

<210> 97
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Gly
<222> (1)..(1)
<223> Gly with the chemical modification described in the specification

<220>
<221> Lys
<222> (10)..(10)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (30)..(30)
<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>

<221> Arg
<222> (34)..(34)
<223> Arg with the chemical modification described in the specification

<400> 97

Gly Ile Lys Pro Glu Ala Pro Gly Glu Lys Ala Ser Pro Glu Glu Leu
1 5 10 15

Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Cys Thr Arg
20 25 30

Gln Arg Tyr
35

<210> 98
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Gly
<222> (1)..(1)
<223> Gly with the chemical modification described in the specification

<220>
<221> Lys
<222> (10)..(10)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys with the chemical modification described in the specification

<220>
<221> Arg
<222> (34)..(34)
<223> Arg with the chemical modification described in the specification

<400> 98

Gly Ile Ser Pro Glu Ala Pro Gly Glu Lys Ala Ser Pro Glu Glu Leu
1 5 10 15

Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Cys Val Thr Arg

20

25

30

Gln Arg Tyr
35

<210> 99
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ala
<222> (1)..(1)
<223> Ala with the chemical modification described in the specification

<220>
<221> Lys
<222> (10)..(10)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys with the chemical modification described in the specification

<220>
<221> Arg
<222> (34)..(34)
<223> Arg with the chemical modification described in the specification

<400> 99

Ala Ile Lys Pro Glu Ala Pro Gly Glu Lys Ala Ser Pro Glu Glu Leu
1 5 10 15

Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Cys Val Thr Arg
20 25 30

Gln Arg Tyr
35

<210> 100
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ala
<222> (1)..(1)
<223> Ala with the chemical modification described in the specification

<220>
<221> Lys
<222> (10)..(10)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys with the chemical modification described in the specification

<220>
<221> Arg
<222> (34)..(34)
<223> Arg with the chemical modification described in the specification

<400> 100

Ala	Ile	Lys	Pro	Glu	Ala	Pro	Gly	Glu	Lys	Ala	Ser	Pro	Glu	Glu	Leu
1				5					10					15	

Asn	Arg	Tyr	Tyr	Ala	Ser	Leu	Arg	His	Tyr	Leu	Asn	Cys	Val	Thr	Arg
			20					25					30		

Gln	Arg	Tyr
		35

<210> 101
<211> 34
<212> PRT
<213> Homo sapiens

<400> 101

Ile	Lys	Pro	Glu	Ala	Pro	Gly	Glu	Asp	Ala	Ser	Pro	Glu	Glu	Leu	Asn
1				5					10					15	

Arg	Tyr	Tyr	Ala	Ser	Leu	Arg	His	Tyr	Leu	Asn	Leu	Val	Thr	Arg	Gln
			20				25						30		

Arg Tyr

<210> 102
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Conjugate 1

<220>
<221> Ala
<222> (1)..(1)
<223> Ala with the chemical modification described in the specification

<220>
<221> Lys
<222> (10)..(10)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>
<221> Arg
<222> (33)..(33)
<223> Arg with the chemical modification described in the specification

<400> 102

Ala	Ile	Lys	Pro	Glu	Ala	Pro	Gly	Glu	Lys	Ala	Ser	Pro	Glu	Glu	Leu
1				5				10					15		

Asn	Arg	Tyr	Tyr	Ala	Ser	Leu	Arg	His	Tyr	Leu	Asn	Leu	Cys	Thr	Arg
			20					25					30		

Gln Arg Tyr
35

<210> 103
<211> 35
<212> PRT
<213> Artificial Sequence

<220>

<223> Conjugate 2

<220>

<221> Ala

<222> (1)..(1)

<223> Ala with the chemical modification described in the specification

<220>

<221> Lys

<222> (10)..(10)

<223> Lys with the chemical modification described in the specification

<220>

<221> Cys

<222> (30)..(30)

<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>

<221> Arg

<222> (34)..(34)

<223> Arg with the chemical modification described in the specification

<400> 103

Ala	Ile	Lys	Pro	Glu	Ala	Pro	Gly	Glu	Lys	Ala	Ser	Pro	Glu	Glu	Leu
1			5					10					15		

Asn	Arg	Tyr	Tyr	Ala	Ser	Leu	Arg	His	Tyr	Leu	Asn	Leu	Cys	Thr	Arg
		20					25						30		

Gln	Arg	Tyr
		35

<210> 104

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> Conjugate 3

<220>

<221> Ala

<222> (1)..(1)

<223> Ala with the chemical modification described in the specification

<220>

<221> Lys

<222> (10)..(10)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (30)..(30)
<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>
<221> Arg
<222> (34)..(34)
<223> Arg with the chemical modification described in the specification

<400> 104

Ala	Ile	Lys	Pro	Glu	Ala	Pro	Gly	Glu	Lys	Ala	Ser	Pro	Glu	Glu	Leu
1				5					10					15	

Asn	Arg	Tyr	Tyr	Ala	Ser	Leu	Arg	His	Tyr	Leu	Asn	Leu	Cys	Thr	Arg
			20					25					30		

Gln	Arg	Tyr
		35

<210> 105
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Conjugate 4

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification described in the specification

<220>
<221> Lys
<222> (9)..(9)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys with the chemical modification described in the specification

<220>
<221> Arg

<222> (33)..(33)
<223> Arg with the chemical modification described in the specification

<400> 105

Ile	Lys	Pro	Glu	Ala	Pro	Gly	Glu	Lys	Ala	Ser	Pro	Glu	Glu	Leu	Asn
1				5					10					15	

Arg	Tyr	Tyr	Ala	Ser	Leu	Arg	His	Tyr	Leu	Asn	Leu	Cys	Thr	Arg	Gln
			20					25					30		

Arg Tyr

<210> 106
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Conjugate 5

<220>
<221> Ala
<222> (1)..(1)
<223> Ala with the chemical modification described in the specification

<220>
<221> Lys
<222> (10)..(10)
<223> Lys with the chemical modification described in the specification

<220>
<221> Lys
<222> (29)..(29)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (30)..(30)
<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>
<221> Arg
<222> (34)..(34)
<223> Arg with the chemical modification described in the specification

<400> 106

Ala Ile Lys Pro Glu Ala Pro Gly Glu Lys Ala Ser Pro Glu Glu Leu
1 5 10 15

Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Lys Cys Thr Arg
20 25 30

Gln Arg Tyr
35

<210> 107
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Conjugate 6

<220>
<221> Ala
<222> (1)..(1)
<223> Ala with the chemical modification described in the specification

<220>
<221> Lys
<222> (10)..(10)
<223> Lys with the chemical modification described in the specification

<220>
<221> Lys
<222> (19)..(19)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (30)..(30)
<223> Cys, wherein the cys is a homocysteine with the chemical
modification described in the specification

<220>
<221> Arg
<222> (34)..(34)
<223> Arg with the chemical modification described in the specification

<400> 107

Ala Ile Lys Pro Glu Ala Pro Gly Glu Lys Ala Ser Pro Glu Glu Leu
1 5 10 15

Asn Arg Lys Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Cys Thr Arg

20

25

30

Gln Arg Tyr
35

<210> 108
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Conjugate 7

<220>
<221> Ala
<222> (1)..(1)
<223> Ala with the chemical modification described in the specification

<220>
<221> Lys
<222> (10)..(10)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (30)..(30)
<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>
<221> Gln
<222> (33)..(33)
<223> Gln with the chemical modification described in the specification

<220>
<221> Arg
<222> (34)..(34)
<223> Arg with the chemical modification described in the specification

<400> 108

Ala Ile Lys Pro Glu Ala Pro Gly Glu Lys Ala Ser Pro Glu Glu Leu
1 5 10 15

Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Cys Thr Arg
20 25 30

Gln Arg Tyr
35

<210> 109
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Conjugate 8

<220>
<221> Ala
<222> (1)..(1)
<223> Ala with the chemical modification described in the specification

<220>
<221> Lys
<222> (10)..(10)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (30)..(30)
<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>
<221> Arg
<222> (34)..(34)
<223> Arg with the chemical modification described in the specification

<400> 109

Ala Ile Lys Pro Glu Ala Pro Gly Glu Lys Ala Ser Pro Glu Glu Leu
1 5 10 15

Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Cys Thr Arg
20 25 30

Gln Arg Tyr
35

<210> 110
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Conjugate 9

<220>
<221> Ala
<222> (1)..(1)
<223> Ala with the chemical modification described in the specification

<220>
<221> Lys
<222> (10)..(10)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (30)..(30)
<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>
<221> Arg
<222> (34)..(34)
<223> Arg with the chemical modification described in the specification

<400> 110

Ala	Ile	Arg	Pro	Glu	Ala	Pro	Gly	Glu	Lys	Ala	Ser	Pro	Glu	Glu	Leu
1				5					10					15	

Asn	Arg	Tyr	Tyr	Ala	Ser	Leu	Arg	His	Tyr	Leu	Asn	Trp	Cys	Thr	Arg
			20					25					30		

Gln	Arg	Tyr
		35

<210> 111
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Conjugate 10

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification described in the specification

<220>
<221> Lys
<222> (9)..(9)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys with the chemical modification described in the specification

<220>
<221> Arg
<222> (33)..(33)
<223> Arg with the chemical modification described in the specification

<400> 111

Ile Arg Pro Glu Ala Pro Gly Glu Lys Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Trp Cys Thr Arg Gln
20 25 30

Arg Tyr

<210> 112
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> Conjugate 11

<220>
<221> Lys
<222> (1)..(1)
<223> Lys with the chemical modification described in the specification

<220>
<221> Lys
<222> (8)..(8)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (28)..(28)
<223> Cys with the chemical modification described in the specification

<220>
<221> Arg
<222> (32)..(32)
<223> Arg with the chemical modification described in the specification

<400> 112

Lys Pro Glu Ala Pro Gly Glu Lys Ala Ser Pro Glu Glu Leu Asn Arg
1 5 10 15

Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Cys Thr Arg Gln Arg
20 25 30

Tyr

<210> 113

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> Conjugate 12

<220>

<221> Ile

<222> (1)..(1)

<223> Ile with the chemical modification described in the specification

<220>

<221> Lys

<222> (9)..(9)

<223> Lys with the chemical modification described in the specification

<220>

<221> Leu

<222> (29)..(29)

<223> Leu, wherein the leu is a norleucine with the chemical
modification described in the specification

<220>

<221> Arg

<222> (33)..(33)

<223> Arg with the chemical modification described in the specification

<400> 113

Ile Lys Pro Glu Ala Pro Gly Glu Lys Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Leu Val Thr Arg
20 25 30

Gln Arg Tyr
35

<210> 114
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Conjugate 13

<220>
<221> Ile
<222> (1)..(1)
<223> Ile with the chemical modification described in the specification

<220>
<221> Lys
<222> (10)..(10)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (30)..(30)
<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>
<221> Arg
<222> (34)..(34)
<223> Arg with the chemical modification described in the specification

<400> 114

Ile Lys Pro Glu Ala Pro Gly Glu Lys Ala Ser Pro Glu Glu Leu Asn
1 5 10 15

Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Cys Val Thr Arg
20 25 30

Gln Arg Tyr
35

<210> 115
<211> 36
<212> PRT
<213> Artificial Sequence

<220>

<223> Conjugate 14

<220>

<221> Ala

<222> (1)..(1)

<223> Ala with the chemical modification described in the specification

<220>

<221> Lys

<222> (22)..(22)

<223> Lys with the chemical modification described in the specification

<220>

<221> Cys

<222> (30)..(30)

<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>

<221> Arg

<222> (34)..(34)

<223> Arg with the chemical modification described in the specification

<400> 115

Ala	Ile	Lys	Pro	Glu	Ala	Pro	Gly	Glu	Asp	Ala	Ser	Pro	Glu	Glu	Leu
1			5					10					15		

Asn	Arg	Tyr	Tyr	Ala	Lys	Leu	Arg	His	Tyr	Leu	Asn	Leu	Cys	Val	Thr
		20					25						30		

Arg	Gln	Arg	Tyr
			35

<210> 116

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> Conjugate 15

<220>

<221> Ala

<222> (1)..(1)

<223> Ala with the chemical modification described in the specification

<220>

<221> Lys

<222> (21)..(21)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (30)..(30)
<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>
<221> Arg
<222> (34)..(34)
<223> Arg with the chemical modification described in the specification

<400> 116

Ala	Ile	Lys	Pro	Glu	Ala	Pro	Gly	Glu	Asp	Ala	Ser	Pro	Glu	Glu	Leu
1				5				10					15		

Asn	Arg	Tyr	Tyr	Lys	Ser	Leu	Arg	His	Tyr	Leu	Asn	Leu	Cys	Val	Thr
			20					25					30		

Arg	Gln	Arg	Tyr
			35

<210> 117
<211> 36
<212> PRT
<213> Artificial Sequence

<220>
<223> Conjugate 16

<220>
<221> Ala
<222> (1)..(1)
<223> Ala with the chemical modification described in the specification

<220>
<221> Lys
<222> (6)..(6)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (30)..(30)
<223> Cys with the chemical modification described in the specification

<220>
<221> Arg

<222> (34)..(34)
<223> Arg with the chemical modification described in the specification

<400> 117

Ala Ile Lys Pro Glu Lys Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu
1 5 10 15

Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Cys Val Thr
20 25 30

Arg Gln Arg Tyr
35

<210> 118
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Conjugate 17

<220>
<221> Gly
<222> (1)..(1)
<223> Gly with the chemical modification described in the specification

<220>
<221> Lys
<222> (10)..(10)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys with the chemical modification described in the specification

<220>
<221> Arg
<222> (34)..(34)
<223> Arg with the chemical modification described in the specification

<400> 118

Gly Ile Lys Pro Glu Ala Pro Gly Glu Lys Ala Ser Pro Glu Glu Leu
1 5 10 15

Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Cys Val Thr Arg
20 25 30

Gln Arg Tyr
35

<210> 119
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Conjugate 18

<220>
<221> Gly
<222> (1)..(1)
<223> Gly with the chemical modification described in the specification

<220>
<221> Lys
<222> (10)..(10)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys with the chemical modification described in the specification

<220>
<221> Arg
<222> (34)..(34)
<223> Arg with the chemical modification described in the specification

<400> 119

Gly Ile Lys Pro Glu Ala Pro Gly Glu Lys Ala Ser Pro Glu Glu Leu
1 5 10 15

Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Cys Val Thr Arg
20 25 30

Gln Arg Tyr
35

<210> 120
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Conjugate 19

<220>
<221> Ala
<222> (1)..(1)
<223> Ala with the chemical modification described in the specification

<220>
<221> Lys
<222> (10)..(10)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys with the chemical modification described in the specification

<220>
<221> Arg
<222> (34)..(34)
<223> Arg with the chemical modification described in the specification

<400> 120

Ala	Ile	Lys	Pro	Glu	Ala	Pro	Gly	Glu	Lys	Ala	Ser	Pro	Glu	Glu	Leu
1			5					10					15		

Asn	Arg	Tyr	Tyr	Ala	Ser	Leu	Arg	His	Tyr	Leu	Asn	Cys	Val	Thr	Arg
		20					25					30			

Gln	Arg	Tyr
		35

<210> 121
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Conjugate 20

<220>
<221> Gly
<222> (1)..(1)
<223> Gly with the chemical modification described in the specification

<220>
<221> Lys

<222> (10)..(10)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>
<221> Arg
<222> (34)..(34)
<223> Arg with the chemical modification described in the specification

<400> 121

Gly	Ile	Lys	Pro	Glu	Ala	Pro	Gly	Glu	Lys	Ala	Ser	Pro	Glu	Glu	Leu
1				5					10					15	

Asn	Arg	Tyr	Tyr	Ala	Ser	Leu	Arg	His	Tyr	Leu	Asn	Cys	Val	Thr	Arg
			20					25					30		

Gln	Arg	Tyr
		35

<210> 122
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Conjugate 21

<220>
<221> Ala
<222> (1)..(1)
<223> Ala with the chemical modification described in the specification

<220>
<221> Lys
<222> (10)..(10)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (30)..(30)
<223> Cys with the chemical modification described in the specification

<220>
<221> Arg

<222> (34)..(34)
<223> Arg with the chemical modification described in the specification

<400> 122

Ala	Ile	Lys	Pro	Glu	Ala	Pro	Gly	Glu	Lys	Ala	Ser	Pro	Glu	Glu	Leu
1				5					10					15	

Asn	Arg	Tyr	Tyr	Ala	Ser	Leu	Arg	His	Tyr	Leu	Asn	Leu	Cys	Thr	Arg
			20					25					30		

Gln	Arg	Tyr
		35

<210> 123
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Conjugate 22

<220>
<221> Gly
<222> (1)..(1)
<223> Gly with the chemical modification described in the specification

<220>
<221> Lys
<222> (10)..(10)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>
<221> Arg
<222> (34)..(34)
<223> Arg with the chemical modification described in the specification

<400> 123

Gly	Ile	Lys	Pro	Glu	Ala	Pro	Gly	Glu	Lys	Ala	Ser	Pro	Glu	Glu	Leu
1				5					10					15	

Asn	Arg	Tyr	Tyr	Ala	Ser	Leu	Arg	His	Tyr	Leu	Asn	Cys	Val	Thr	Arg
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

20

25

30

Gln Arg Tyr
35

<210> 124
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Conjugate 23

<220>
<221> Ala
<222> (1)..(1)
<223> Ala with the chemical modification described in the specification

<220>
<221> Lys
<222> (10)..(10)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys with the chemical modification described in the specification

<220>
<221> Arg
<222> (34)..(34)
<223> Arg with the chemical modification described in the specification

<400> 124

Ala Ile Lys Pro Glu Ala Pro Gly Glu Lys Ala Ser Pro Glu Glu Leu
1 5 10 15

Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Cys Val Thr Arg
20 25 30

Gln Arg Tyr
35

<210> 125
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Conjugate 24

<220>
<221> Gly
<222> (1)..(1)
<223> Gly with the chemical modification described in the specification

<220>
<221> Lys
<222> (10)..(10)
<223> Lys with the chemical modification described in the specification

<220>
<221> Glu
<222> (29)..(29)
<223> Glu with the chemical modification described in the specification

<220>
<221> Arg
<222> (34)..(34)
<223> Arg with the chemical modification described in the specification

<400> 125

Gly	Ile	Ser	Pro	Glu	Ala	Pro	Gly	Glu	Lys	Ala	Ser	Pro	Glu	Glu	Leu
1				5				10					15		

Asn	Arg	Tyr	Tyr	Ala	Ser	Leu	Arg	His	Tyr	Leu	Asn	Glu	Val	Thr	Arg
			20					25					30		

Gln	Arg	Tyr
		35

<210> 126
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Conjugate 25

<220>
<221> Ala
<222> (1)..(1)
<223> Ala with the chemical modification described in the specification

<220>

<221> Lys
<222> (10)..(10)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (30)..(30)
<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>
<221> Arg
<222> (34)..(34)
<223> Arg with the chemical modification described in the specification

<400> 126

Ala	Ile	Lys	Pro	Glu	Ala	Pro	Gly	Glu	Lys	Ala	Ser	Pro	Glu	Glu	Leu
1				5					10					15	

Asn	Arg	Tyr	Tyr	Ala	Ser	Leu	Arg	His	Tyr	Leu	Asn	Leu	Cys	Thr	Arg
			20					25					30		

Gln	Arg	Tyr
		35

<210> 127
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Conjugate 26

<220>
<221> Gly
<222> (1)..(1)
<223> Gly with the chemical modification described in the specification

<220>
<221> Lys
<222> (10)..(10)
<223> Lys with the chemical modification described in the specification

<220>
<221> Cys
<222> (30)..(30)
<223> Cys, wherein the cys is a homocysteine with the chemical modification described in the specification

<220>
<221> Arg
<222> (34)..(34)
<223> Arg with the chemical modification described in the specification

<400> 127

Gly Ile Lys Pro Glu Ala Pro Gly Glu Lys Ala Ser Pro Glu Glu Leu
1 5 10 15

Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Cys Thr Arg
20 25 30

Gln Arg Tyr
35

<210> 128
<211> 107
<212> PRT
<213> Homo sapiens

<400> 128

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45

Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Leu
85 90 95

Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105

<210> 129
<211> 119
<212> PRT
<213> Homo sapiens

<400> 129

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Lys Tyr Asp Gly Ile Tyr Gly Glu Leu Asp Phe Trp Gly Gln Gly
100 105 110

Thr Leu Val Thr Val Ser Ser
115

<210> 130
<211> 10
<212> PRT
<213> Homo sapiens

<400> 130

Tyr Asp Gly Ile Tyr Gly Glu Leu Asp Phe
1 5 10

<210> 131
<211> 115
<212> PRT
<213> Artificial Sequence

<220>

<223> concatenation of IGHV3-23*01 and IGHJ1*01

<400> 131

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Lys Ala Glu Tyr Phe Gln His Trp Gly Gln Gly Thr Leu Val Thr
100 105 110

Val Ser Ser
115

<210> 132

<211> 98

<212> PRT

<213> Homo sapiens

<400> 132

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35

40

45

Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Lys

<210> 133
 <211> 17
 <212> PRT
 <213> Homo sapiens

<400> 133

Ala Glu Tyr Phe Gln His Trp Gly Gln Gly Thr Leu Val Thr Val Ser
 1 5 10 15

Ser

<210> 134
 <211> 107
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> concatenation of IGKV3-11*01 and IGKJ1*01

<400> 134

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
 20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
 35 40 45

Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Trp
85 90 95

Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105

<210> 135
<211> 95
<212> PRT
<213> Homo sapiens

<400> 135

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45

Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro
85 90 95

<210> 136
<211> 12
<212> PRT
<213> Homo sapiens

<400> 136

Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
1 5 10

<210> 137

<211> 119

<212> PRT

<213> Artificial Sequence

<220>

<223> MSCB97 VH

<400> 137

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Lys Tyr Asp Gly Cys Tyr Gly Glu Leu Asp Phe Trp Gly Gln Gly
100 105 110

Thr Leu Val Thr Val Ser Ser
115

<210> 138

<211> 446

<212> PRT

<213> Artificial Sequence

<220>

<223> MSCB97 HC

<400> 138

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Lys Tyr Asp Gly Cys Tyr Gly Glu Leu Asp Phe Trp Gly Gln Gly
100 105 110

Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe
115 120 125

Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu
130 135 140

Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp
145 150 155 160

Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu
165 170 175

Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser
180 185 190

Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro
195 200 205

Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro
210 215 220

Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe
225 230 235 240

Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro
245 250 255

Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val
260 265 270

Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr
275 280 285

Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val
290 295 300

Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys
305 310 315 320

Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser
325 330 335

Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
340 345 350

Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val
355 360 365

Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly
370 375 380

Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp
385 390 395 400

Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp
405 410 415

Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His
420 425 430

Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys
435 440 445

<210> 139
<211> 107
<212> PRT
<213> Artificial Sequence

<220>
<223> MSCB97 VL

<400> 139

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45

Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Leu
85 90 95

Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105

<210> 140
<211> 214
<212> PRT
<213> Artificial Sequence

<220>
<223> MSCB97 LC

<400> 140

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45

Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Leu
85 90 95

Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110

Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125

Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140

Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160

Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175

Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190

Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205

Phe Asn Arg Gly Glu Cys
210

<210> 141
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> MSCB97 HCDR1

<400> 141

Ser Tyr Ala Met Ser
1 5

<210> 142
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> MSCB97 HCDR2

<400> 142

Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

Gly

<210> 143
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> MSCB97 HCDR3

<400> 143

Tyr Asp Gly Cys Tyr Gly Glu Leu Asp Phe
1 5 10

<210> 144
<211> 11
<212> PRT
<213> Artificial Sequence

<220>

<223> MSCB97 LCDR1

<400> 144

Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala
1 5 10

<210> 145

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> MSCB97 LCDR2

<400> 145

Asp Ala Ser Asn Arg Ala Thr
1 5

<210> 146

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> MSCB97 LCDR3

<400> 146

Gln Gln Arg Ser Asn Trp Pro Leu Thr
1 5

<210> 147

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> Cyclic PYY Peptide Compound

<220>

<221> Ala

<222> (1)..(1)

<223> Ala with chemical modification described in the specification

<220>

<221> Cys

<222> (30)..(30)
<223> Cys, wherein the cys is a homocysteine with chemical modification described in the specification

<220>
<221> Arg
<222> (34)..(34)
<223> Arg with chemical modification described in the specification

<400> 147

Ala	Ile	Lys	Pro	Glu	Ala	Pro	Gly	Glu	Asp	Ala	Ser	Pro	Glu	Glu	Leu
1				5					10					15	

Asn	Arg	Tyr	Tyr	Ala	Ser	Leu	Arg	His	Tyr	Leu	Asn	Leu	Cys	Thr	Arg
			20					25					30		

Gln	Arg	Tyr
		35

<210> 148
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ala
<222> (1)..(1)
<223> Ala with chemical modification described in the specification

<220>
<221> Lys
<222> (10)..(10)
<223> Lys with chemical modification described in the specification

<220>
<221> Cys
<222> (30)..(30)
<223> Cys, wherein the cys is a homocysteine with chemical modification described in the specification

<220>
<221> Arg
<222> (34)..(34)
<223> Arg with chemical modification described in the specification

<400> 148

Ala Ile Lys Pro Glu Ala Pro Gly Glu Lys Ala Ser Pro Glu Glu Leu
1 5 10 15

Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Cys Thr Arg
20 25 30

Gln Arg Tyr
35

<210> 149
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Gly
<222> (1)..(1)
<223> Gly with chemical modification described in the specification

<220>
<221> Glu
<222> (29)..(29)
<223> Glu with chemical modification described in the specification

<220>
<221> Arg
<222> (34)..(34)
<223> Arg with chemical modification described in the specification

<400> 149

Gly Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu
1 5 10 15

Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Glu Val Thr Arg
20 25 30

Gln Arg Tyr
35

<210> 150
<211> 35
<212> PRT

<213> Artificial Sequence

<220>

<223> Cyclic PYY Peptide Compound

<220>

<221> Gly

<222> (1)..(1)

<223> Gly with chemical modification described in the specification

<220>

<221> Lys

<222> (10)..(10)

<223> Lys with chemical modification described in the specification

<220>

<221> Glu

<222> (29)..(29)

<223> Glu with chemical modification described in the specification

<220>

<221> Arg

<222> (34)..(34)

<223> Arg with chemical modification described in the specification

<400> 150

Gly	Ile	Lys	Pro	Glu	Ala	Pro	Gly	Glu	Lys	Ala	Ser	Pro	Glu	Glu	Leu
1				5				10					15		

Asn	Arg	Tyr	Tyr	Ala	Ser	Leu	Arg	His	Tyr	Leu	Asn	Glu	Val	Thr	Arg
			20					25					30		

Gln	Arg	Tyr
		35

<210> 151

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> Cyclic PYY Peptide Compound

<220>

<221> Gly

<222> (1)..(1)

<223> Gly with chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys with chemical modification described in the specification

<220>
<221> Arg
<222> (34)..(34)
<223> Arg with chemical modification described in the specification

<400> 151

Gly Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu
1 5 10 15

Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Cys Val Thr Arg
20 25 30

Gln Arg Tyr
35

<210> 152
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Gly
<222> (1)..(1)
<223> Gly with chemical modification described in the specification

<220>
<221> Lys
<222> (10)..(10)
<223> Lys with chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys with chemical modification described in the specification

<220>
<221> Arg
<222> (34)..(34)
<223> Arg with chemical modification described in the specification

<400> 152

Gly Ile Lys Pro Glu Ala Pro Gly Glu Lys Ala Ser Pro Glu Glu Leu
1 5 10 15

Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Cys Val Thr Arg
20 25 30

Gln Arg Tyr
35

<210> 153
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ala
<222> (1)..(1)
<223> Ala with chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys with chemical modification described in the specification

<220>
<221> Arg
<222> (34)..(34)
<223> Arg with chemical modification described in the specification

<400> 153

Ala Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu
1 5 10 15

Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Cys Val Thr Arg
20 25 30

Gln Arg Tyr
35

<210> 154
<211> 35
<212> PRT

<213> Artificial Sequence

<220>

<223> Cyclic PYY Peptide Compound

<220>

<221> Ala

<222> (1)..(1)

<223> Ala with chemical modification described in the specification

<220>

<221> Lys

<222> (10)..(10)

<223> Lys with chemical modification described in the specification

<220>

<221> Cys

<222> (29)..(29)

<223> Cys with chemical modification described in the specification

<220>

<221> Arg

<222> (34)..(34)

<223> Arg with chemical modification described in the specification

<400> 154

Ala	Ile	Lys	Pro	Glu	Ala	Pro	Gly	Glu	Lys	Ala	Ser	Pro	Glu	Glu	Leu
1				5				10					15		

Asn	Arg	Tyr	Tyr	Ala	Ser	Leu	Arg	His	Tyr	Leu	Asn	Cys	Val	Thr	Arg
		20					25					30			

Gln	Arg	Tyr
		35

<210> 155

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> Cyclic PYY Peptide Compound

<220>

<221> Ala

<222> (1)..(1)

<223> Ala with chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys with chemical modification described in the specification

<220>
<221> Arg
<222> (34)..(34)
<223> Arg with chemical modification described in the specification

<400> 155

Ala Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu
1 5 10 15

Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Cys Val Thr Arg
20 25 30

Gln Arg Tyr
35

<210> 156
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Cyclic PYY Peptide Compound

<220>
<221> Ala
<222> (1)..(1)
<223> Ala with chemical modification described in the specification

<220>
<221> Lys
<222> (10)..(10)
<223> Lys with chemical modification described in the specification

<220>
<221> Cys
<222> (29)..(29)
<223> Cys with chemical modification described in the specification

<220>
<221> Arg
<222> (34)..(34)
<223> Arg with chemical modification described in the specification

<400> 156

Ala Ile Lys Pro Glu Ala Pro Gly Glu Lys Ala Ser Pro Glu Glu Leu
1 5 10 15

Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Cys Val Thr Arg
20 25 30

Gln Arg Tyr
35